Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT00044564

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00044564. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant. In patients with metastatic disease, the options are limited. The taxanes are among the most commonly used class of chemotherapy agents in clinical oncology today but they are not effective in renal cancers; the development of Bay 59-8862 targets taxane-resistant tumors and the current protocol is designed to test the safety and efficacy of Bay 59-8862 in patients with advanced renal cell carcinoma.

Study identification

NCT ID: NCT00044564
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bayer; Industry
Enrollment: 54 participants

Conditions and interventions

Conditions

Carcinoma, Renal Cell

Interventions

Bay 59-8862 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2001 (Type not available)
Primary completion: Not listed
Completion: Jan 2003 (Actual)
Last update posted: Dec 19, 2014

2001 – 2003

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Not listed	La Jolla	California	92037	—
Not listed	Muncie	Indiana	47304	—
Not listed	New Orleans	Louisiana	70121-2484	—
Not listed	Baltimore	Maryland	21201-1595	—
Not listed	Greenbelt	Maryland	20770	—
Not listed	Detroit	Michigan	48201-9027	—
Not listed	Southfield	Michigan	48075	—
Not listed	St Louis	Missouri	63104	—
Not listed	St Louis	Missouri	63110	—
Not listed	Billings	Montana	59101	—
Not listed	New Brunswick	New Jersey	08901	—
Not listed	Salt Lake City	Utah	84108	—
Not listed	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00044564, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 19, 2014 · Synced Nov 12, 2026